The case for small partners

When KuDos Ltd. licensed the AQ4N topoisomerase II inhibitor and DNA intercalator from BTG International plc (LSE:BGC, London, U.K.) in March 2002, it intended to develop the compound through Phase II before seeking a partner. The company then decided it needed some help, but didn't want to hand off the product to a big pharma

Read the full 554 word article

How to gain access

Continue reading with a
two-week free trial.